

1 Human Papillomavirus Infection Rate by  
2 Genotype and Vaccination Rates in  
3 Canada: Canadian Health Measures  
4 Survey 2009 to 2013

5 Authors

6 1. Yi-Sheng Chao, MD MPH PhD\*  
7 Independent researcher  
8 Email: [chaoyisheng@post.harvard.edu](mailto:chaoyisheng@post.harvard.edu)  
9 \*Corresponding author

10  
11  
12

## 13 Abstract

### 14 Background

15 An infection with certain HPV genotypes can lead to cancer or genital warts. HPV can be  
16 detected with PCR-based tests, and some genotypes can be prevented by vaccines. However,  
17 since the infection rates of various HPV genotypes have not been well reported, the present study  
18 aims to provide this information.

### 19 Methods

20 The Canadian Health Measures Survey (CHMS) is an ongoing biannual national survey.  
21 Between 2009 and 2011, it sampled a nationally representative sample of females aged 14 to 59  
22 years to determine the infection rates of 46 HPV genotypes. Females aged 9 to 29 years and 9 to  
23 59 years were asked whether they received HPV vaccines between 2009 to 2011 (cycle 2) and  
24 2012 to 2013 (cycle 3), respectively. The reported infection rates and vaccination proportions  
25 were weighted and adjusted for the survey design.

### 26 Results

27 Among the estimated 10,592,968 females aged 14 to 59 years at cycle 2, the HPV genotypes  
28 with the highest infection rates were 16, 62, 74, and 54, and the rates were 3.42% (95% CI =  
29 1.67% to 5.17%), 2.14% (95% CI = 0.68% to 3.59%), 2.1% (95% CI = 0.51% to 3.69%), and  
30 2.04% (95% CI = 0.38% to 3.7%), respectively. There were an estimated 6,569,100 and  
31 11,603,752 females aged 9 to 29 and 9 to 59 years at cycles 2 and 3, respectively. The  
32 proportions receiving a HPV vaccine were 13.55% (11.18% to 15.92%) and 12.3% (9.8% to  
33 14.79%), respectively. The estimated numbers of females that received HPV vaccines were  
34 890,197 and 1,427,000, respectively.

### 35 Conclusion

36 Canada is one of the few countries that conduct national surveys to determine HPV infection  
37 rates by genotype, which are not limited to the surveillance of carcinogenic genotypes. Our study  
38 found discrepancies between the HPV genotypes whose infections were the most common, that  
39 could be detected by PCR tests, that were carcinogenic, and that could be prevented by vaccines.  
40 For example, 5 of the 7 genotypes (42, 54, 62, 66, and 74) with infection rates of more than 1%  
41 cannot be detected by PCR tests and are not targeted by vaccines. HPV 51 is carcinogenic,  
42 associated with genital warts, and can be detected by PCR tests, but it is not targeted by vaccines.  
43 We recommend a better alignment of the genotypes targeted by HPV tests and vaccines with  
44 those genotypes with the highest infection rates in Canada.

### 45 Key words

46 Human papillomavirus (HPV); Canadian Health Measures Survey (CHMS); genotype; vaccine;  
47 polymerase chain reaction (PCR) test

48

## 49 Introduction

50 Human papillomavirus (HPV) infection is a major cause of cervical cancer and is related  
51 to other cancer or non-cancer lesions.[1, 2] The risk of cancer depends on the HPV genotypes.[1,  
52 2] Figure 1, based on the findings of the International Agency for Research on Cancer (IARC),  
53 identifies 12 HPV genotypes as carcinogenic (HPVs 16, 18, 31, 33, 45, 52, 58, 35, 39, 51, 56,  
54 and 59) and 1 other as probably carcinogenic (HPV 68).[1, 2] Seven of the 13 genotypes (HPVs  
55 16, 18, 31, 33, 45, 52, and 58) are associated with the occurrence of more than 90% of invasive  
56 cervical cancer.[3] HPV 6 and 11 are associated with more than 90% of genital warts.[4] The  
57 prevalence of HPV infection differs by countries. Globally, in 2012, HPV infection was reported  
58 to be prevalent among 10% of healthy women.[5] The infection rate ranges from 6.6% in Europe  
59 to 22.9% in Africa, and HPV 16 infection is the most common among all HPV genotypes.[5] In  
60 Canada, HPV is estimated to be the most common sexually transmitted disease, and more than  
61 70% of sexually active Canadians are expected to have HPV infection in their lifetime.[6] It is  
62 estimated that 6.2% of individuals with normal cervical cytology were infected with HPV 16 or  
63 18.[7, 8] In terms of infection detection, polymerase chain reaction (PCR) based tests can detect  
64 at least 13 high-risk genotypes (16, 18, 31, 33, 45, 52, 58, 35, 39, 51, 56, 59, and 68) and are  
65 used for cervical cancer screening.[8] Those individuals identified with active HPV infection  
66 may be referred to cervical exams for confirmation.[8] Currently, HPV tests have not been  
67 included in routine cancer screening programs in Canada.[1]

68 Vaccination is an important strategy to prevent HPV infection[7, 9], and HPV vaccines  
69 have been approved in Canada since 2006.[10] Between 2007 and 2010, public vaccination  
70 programs began to be implemented for girls in various Canadian jurisdictions.[10] These public  
71 vaccination programs have been expanded and now are available to other populations.[10]  
72 Several HPV genotypes are targeted by vaccines, especially 6, 11, 16, and 18.[10] Also, other  
73 vaccines can be used to additionally target HPV 31, 33, 45, 52, and 58.[10] In Canada, the  
74 vaccination rates found by various studies are estimated to be 69.62% and 18.66% for in-school  
75 programs and community-based programs, respectively.[4] The vaccination rates for girls  
76 eligible for HPV vaccination programs vary to a great extent between Canadian jurisdictions,  
77 from 40% in the Northwest Territories to 91% in Newfoundland.[11]

78 HPV genotypes differ with respect to the development of various lesions, as to whether  
79 they can be detected by available HPV tests, and as to whether they can be prevented by  
80 vaccination. The infection rates of different HPV genotypes provide important information for  
81 comparison with the assessment of potential disease burden, detectability via PCR tests, and  
82 vaccine effectiveness. However, the estimates for HPV infection rates and vaccination rates are  
83 based on sporadic reports and diverse data sources. Such information is crucial for assessing the  
84 effectiveness of public vaccination programs. Based on nationally representative Canadian data,  
85 the present study reports on HPV infection rates by genotype and HPV vaccination rates.

## 86 Methods

87 The Canadian Health Measures Survey (CHMS) is an ongoing biannual national  
88 biomonitoring survey that has interviewed Canadians since 2007.[12-16] Canadians who were  
89 full-time military members, reserve residents, and institutional residents—less than 4% of the  
90 population—were excluded from the sampling.[16, 17] More than 5,000 participants were  
91 interviewed in each of the 5 cycles that released data before Dec 2020.[12, 15-17] In addition to  
92 face-to-face interviews, biological samples were obtained from the participants to determine  
93 levels of various biomarkers or chemicals.[12-15, 18] By adjusting for the sampling strategies

94 and bootstrap weights, about 30 million Canadians were estimated for each of the 5 cycles, and  
95 about half of them were female.[12, 14, 15, 17] Population characteristics and the numbers of  
96 population by age were published elsewhere.[12, 14, 15, 19, 20]

97 In cycles 2 and 3, conducted between 2009 to 2011 and 2012 to 2013, respectively,  
98 participants were asked whether they had received a HPV vaccine.[21] In cycle 2, 1,576 female  
99 respondents aged 9 to 29 years were asked[21], and in cycle 3, 1,845 female respondents aged 9  
100 to 59 years were asked.[21] The vaccination rates among eligible Canadians were reported in the  
101 survey.

102 In cycle 2, 46 HPV genotypes were tested using urine samples (6, 11, 13, 16, 18, 26, 30,  
103 31, 32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72,  
104 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, and 97) (see Figure 1).[22] Samples were obtained  
105 from 1,770 female respondents aged 14 to 59 years.[21] The infection rates among eligible  
106 Canadians were reported in the survey.

## 107 Data analysis

108 To adjust for the survey design, bootstrap weights, sampling strata, regions, and personal  
109 weights were used in the data analysis.[12-15, 23, 24] To protect the survey respondents'  
110 confidentiality, the results were vetted based on specific rules, before they were released by the  
111 Research Data Centre to researchers.[25] Only weighted statistics were released[25], and they  
112 needed to meet a minimum sample size requirement.[26-30] To protect participant  
113 confidentiality and prevent participants from being identified using the released data, Statistics  
114 Canada did not allow the release of calculated proportions based on 10 or fewer unweighted  
115 participants. At least one participant in each sampling site for each cycle was required.[12-15] In  
116 total, to meet the minimum sample size requirement, roughly at least 100 respondents were  
117 required for each cycle.[12-15] For these proportions that did not meet the requirement, 95% CIs  
118 could not be released, and so the proportions provided in CHMS data dictionaries were used.[22]  
119 All data analysis was conducted with R (v3.20)[51] and RStudio (v0.98.113).[52]

120 This secondary data analysis was approved by the ethics review committee at the Centre  
121 Hospitalier de l'Université de Montréal. A consent to participate was not required for this  
122 secondary data analysis.

## 123 Results

124 Cycle 2 (2009 to 2011) estimated 10,592,968 female Canadians aged 14 to 59 years. The  
125 HPV genotypes with the highest infection rates were 16, 62, 74, and 54, and the rates were  
126 3.42% (95% CI = 1.67% to 5.17%), 2.14% (95% CI = 0.68% to 3.59%), 2.1% (95% CI = 0.51%  
127 to 3.69%), and 2.04% (95% CI = 0.38% to 3.7%), respectively. Three HPV genotypes (66, 52,  
128 and 42) were estimated to have infection rates between 1% and 2%. The other 39 HPV  
129 genotypes were estimated to have infection rates less than 1%. The unweighted numbers of  
130 participants infected with 28 HPV genotypes were fewer than those required by Statistics Canada,  
131 and so 95% CIs of the infection rates of these HPV genotypes could not be released. Thus, the  
132 infection rates of these genotypes were derived from data dictionaries (11, 13, 26, 30, 31, 32, 33,  
133 35, 40, 43, 44, 45, 61, 68, 69, 70, 71, 72, 73, 82, 83, 85, 86, 87, 89, 90, 91, and 97). As a result,  
134 95% CIs of the infection rates were not determined. No infection was identified with 7 HPV  
135 genotypes (13, 26, 43, 69, 71, 85, and 97).

## 136 Vaccination rates

137 Cycle 2 (2009 to 2011) and cycle 3 (2012 to 2013) estimated 6,569,100 and 11,603,752  
138 female Canadians aged 9 to 29 and 9 to 59 years, respectively. The proportions receiving an

139 HPV vaccine were 13.55% (95% CI = 11.18% to 15.92%) and 12.3% (95% CI = 9.8% to  
140 14.79%), respectively. The numbers of females receiving HPV vaccines with respect to the  
141 respective age ranges at cycles 2 and 3 were 890,197 and 1,427,000, respectively.

### 142 Infection rates, detection, carcinogenicity, and preventability

143 In Figure 1, HPV 16 is carcinogenic,[8] can be detected by PCR-based HPV tests,[31]  
144 and can be prevented by HPV vaccines.[10] However, HPV 16 is not related to genital warts and  
145 is not linked to the genotypes associated with genital warts. In contrast, 5 of the 7 HPV  
146 genotypes (42, 54, 62, 66, and 74) with infection rates of more than 1% cannot be detected by  
147 PCR-based tests (13 genotypes)[31] and are not targeted by HPV vaccines.[10]

148 There were 13 genotypes with infection rates less than 1% (HPVs 32, 35, 40, 44, 61, 72,  
149 81, 83, 84, 87, 89, 90, and 91) that are not carcinogenic, cannot be detected by PCR tests, are not  
150 associated with genital warts, and are not targeted by vaccines. HPVs 6 and 11 are associated  
151 with genital warts and are targeted by vaccines, but they are not carcinogenic and cannot be  
152 detected by PCR tests. HPV 51 is carcinogenic, associated with genital warts, and can be  
153 detected by PCR tests, but it is not targeted by vaccines. HPVs 35, 39, 56, and 59 are  
154 carcinogenic and can be detected by PCR tests, but they are not associated with genital warts and  
155 are not targeted by vaccines. HPVs 53, 68, 73, and 82 can be detected by specific PCR tests (19  
156 genotypes), but they are not carcinogenic, are not associated with genital warts, and are not  
157 targeted by vaccines. HPVs 18, 31, 33, 52, and 58 can be detected by PCR tests (13 genotypes),  
158 are carcinogenic, and are targeted by vaccines (4, 9, 9, 9, and 9 genotypes, respectively), but they  
159 not associated with genital warts. HPV 45 can be detected by PCR tests (13 genotypes), is  
160 carcinogenic, and is associated with genital warts, and is targeted by specific vaccines (9  
161 genotypes). HPV 70 is associated with genital warts, but it is not carcinogenic, cannot be  
162 detected by PCR tests, and is not targeted by vaccines. HPV 30 is possibly carcinogenic and is  
163 associated with genital warts, but it is not carcinogenic and is not targeted by vaccines.

164 Among the HPV genotypes without any identified infection, HPVs 13 and 71 are not  
165 detected by PCR tests, are not carcinogenic, are not associated with genital warts, and are not  
166 targeted by vaccines. HPV 26 can be detected by specific PCR tests (19 genotypes), but is not  
167 carcinogenic, is not associated with genital warts, and is not targeted by vaccines. HPV 43 is  
168 associated with genital warts, but it is not detected by PCR tests, is not carcinogenic, and is not  
169 targeted by vaccines. HPVs 69, 85, and 97 are possibly carcinogenic, but they cannot be detected  
170 by PCR tests, are not associated with genital warts, and not targeted by vaccines.

## 171 Discussion

172 The present study reports the HPV infection rates by genotype determined at a time when  
173 HPV vaccines were beginning to be used increasingly and were being promoted by public  
174 programs in Canada. Such information is crucial for assessing the epidemiology of HPV  
175 infection by genotype and the effectiveness of HPV vaccines. More importantly, we identified  
176 discrepancies between the HPV genotypes whose infections are prevalent, that can be detected  
177 by HPV tests, that are associated with cancer or genital warts, and that are targeted by vaccines.  
178 Since the HPV genotypes considered carcinogenic may change over time, depending on  
179 available evidence,[32-35] the usefulness of commercially available PCR tests approved in  
180 Canada—especially those reviewed by Health Technology Assessment (HTA)—may be  
181 somewhat limited with respect to the genotypes chosen for HPV vaccines, and the choice of  
182 targets for HPV infection surveillance.

## 183 Genotypes with high infection rates

184 HPV 16 is carcinogenic[8] and is the most common HPV infection in the world.[5] It also  
185 is the genotype with the highest infection rates in Canada, a fact that has been recognized by  
186 other researchers.[5, 36] The estimated infection rates of HPV 16 varies from 3.5% in healthy  
187 women in North America[5] to 4.7% of the normal cytology[36] in Canada. The present study  
188 estimates that between 2009 and 2011, 3.42% of Canadian females aged 14 to 59 years were  
189 infected with HPV 16. However, studies disagree about the other HPV genotypes that have high  
190 infection rates and the percentage of their infection rates. One study has estimated that HPVs 53  
191 and 52 are the genotypes with the second and third highest infection rates in healthy women in  
192 North America.[5] In this study, four out of the five HPV genotypes studied were carcinogenic  
193 (HPVs 16, 18, 39, and 52), and the other one (HPV 53) was possibly carcinogenic.[5] In another  
194 study that systematically reviewed and meta-analyzed trials or studies in Canada, HPVs 18 and  
195 31 were the genotypes with the second and third highest infection rates.[36] In this study, 9 out  
196 of the 10 HPV genotypes studied were carcinogenic, and the other one (HPV 66) was possibly  
197 carcinogenic.[36] Results from previous studies may suggest that researchers' interests were  
198 focused mostly on carcinogenic HPV genotypes, so infections from other HPV genotypes may  
199 not have been as well studied as they should have been. The present study found that the  
200 infections of several possibly carcinogenic genotypes (especially HPV 66) were more prevalent  
201 than many carcinogenic HPV genotypes.

202 The infection rates of carcinogenic HPV genotypes were mostly lower than those rates  
203 estimated by synthesizing primary studies of various characteristics. For example, based on a  
204 2014 meta-analysis, HPVs 18, 31, 66, 45, and 59 (ordered by infection rates) were the  
205 carcinogenic genotypes estimated to be prevalent in more than 1% of normal cytology.[36]  
206 However, in the nationally representative sample of females aged 14 to 59 years surveyed in the  
207 CHMS, the infection rates of these genotypes were 0.51%, 0.45%, 1.83%, 0.32%, and 0.43%,  
208 respectively. It is unclear whether the included smaller studies tended to obtain more high-risk  
209 individuals or whether small-study effects have been well addressed.[37] The reasons for the  
210 discrepancies in the estimated infection rates between studies were not clear. Thus, an extensive  
211 review may be required of the population characteristics between studies and follow-ups of  
212 infection trends in future cycles of the CHMS.

213 A lack of detection methods or preventive measures for certain HPV genotypes with the  
214 highest infection rates does not mean these genotypes are not associated with adverse health  
215 outcomes. Among the genotypes that could not be detected by PCR tests (12 to 18 genotypes) in  
216 a health technology assessment (HTA) review, HPVs 42, 62, and 74 were associated with the  
217 development of cervical lesions, cervical intraepithelial neoplasia.[38] The PCR tests reviewed  
218 by the HTA were the tests that are used in primary screening, and many have been approved for  
219 clinical use in Canada.[31] In Figure 1, HPVs 42 and 54 are associated with genital warts.[38]  
220 We did not identify the major studies that have investigated the health impact of these genotypes  
221 with high infection rates in Canada.

## 222 Detection and carcinogenicity

223 The HPV genotypes that PCR tests aim to detect include the 12 carcinogenic genotypes  
224 identified by the IARC classification updated in 2012.[31] HPVs 26, 53, 66, 68, 73, and 82 are  
225 the genotypes that can be detected using the PCR tests that can detect up to 18 genotypes.[31] In  
226 the IARC 2012 update, HPV 68 is considered probably carcinogenic, and HPVs 26, 53, 66, 73,  
227 and 82 are possibly carcinogenic.[33] HPVs 26 and 73 also are associated with common skin  
228 lesions.[38]

229           However, nine possibly carcinogenic genotypes (HPVs 5, 8, 30, 34, 67, 69, 70, 85, and  
230 97) cannot be detected with the PCR tests (12 to 18 genotypes) reviewed by the HTA. In Figure  
231 1, the HPV genotypes associated with genital warts cannot be detected by the PCR tests that can  
232 identify 12 to 18 genotypes.[31] Moreover, vaccine-preventable HPV genotypes (6 and 11)  
233 cannot be detected by these PCR tests. The role of these commercially available PCR tests may  
234 be limited in detecting some possibly carcinogenic genotypes and those associated with genital  
235 warts. With respect to policy evaluation, the genotypes that are not targeted by these PCR tests  
236 should be considered when assessing HPV-related disease burden or the effectiveness of  
237 preventive measures.

238           Moreover, one major limitation of many commercially available PCR tests is that only  
239 positive or negative results are reported, and the exact HPV genotypes detected are not  
240 reported.[31] If the HPV genotypes can be reported by PCR tests, this may help efforts to  
241 prevent further spreading of these genotypes.

#### 242 [Changes to the carcinogenicity classification](#)

243           The 12 genotypes that can be detected by PCR tests match those classified carcinogenic  
244 genotypes identified in the IARC 2012 update.[33] Figure 1 shows the additional genotypes that  
245 can be identified by PCR tests that can detect 13, 14, or 18 genotypes that are probably or  
246 possibly carcinogenic as defined by the IARC. Over time, changes have been made to the  
247 carcinogenicity classifications of HPV genotypes.[35, 39] Although the present study found that  
248 the infection rates of the possibly carcinogenic genotypes were not high, except for HPV 66,  
249 their potential for carcinogenicity requires constant surveillance. Since some genotypes have  
250 high infection rates, it may be easier to identify the patients infected with these genotypes for  
251 follow-up. The CHMS can be used to assess related changes in the cancer burden attributable to  
252 HPV infection, and which is preventable by vaccines.[40] The present study did not consider  
253 several possibly carcinogenic genotypes (HPVs 5, 8, and 34) that may need follow-up in future  
254 CHMS cycles.

#### 255 [Vaccination rates](#)

256           The vaccination rates reported in the two CHMS cycles were based on two different age  
257 ranges—9 to 29 and 9 to 59 years—and these rates decreased slightly over the two cycles from  
258 13.55% to 12.3%, respectively. However, the absolute numbers of females receiving the  
259 vaccines over the two CHMS cycles increased more than 60%. Vaccination programs in Canada  
260 are expanding with public support.[9, 11] The target population also changed from school-age  
261 girls in many provinces to other age groups and males.[41] Globally, between 2006 and 2019,  
262 HPV vaccination indicated an increasing trend, and Canada was one of the countries with more  
263 than 83% coverage among school-aged girls.[42] However, a considerable variability exists in  
264 HPV vaccination rates across Canada.[42] In a recent estimate, the coverage rates of school-  
265 based HPV vaccination programs ranged from 59.4% in Ontario to 88.4% in Prince Edward  
266 Island for girls in the 2016–2017 school year, compared to 52.5% in Ontario to 88.2% in  
267 Newfoundland and Labrador for girls in the 2008–2009 school year.[43] Continuous efforts to  
268 vaccinate younger generations will lead to better vaccination coverage.

269           It has been estimated that HPV vaccines can reduce cervical cancer and other HPV-  
270 related cancers.[40] However, since most vaccines act against four or nine HPV genotypes,[10]  
271 many of the genotypes with high infection rates in this study were not targeted. Nevertheless,  
272 some evidence exists that cross-reactivity may be induced by HPV vaccines to act against non-  
273 genital HPVs.[44] At a population level, the herd immunity that protects unvaccinated  
274 individuals also can be achieved when more individuals are vaccinated.[45] However, the exact

275 impact on infection rates of the genotypes not targeted by vaccines remains unclear. We expect  
276 vaccination rates to continue increasing, and the influence of vaccines on the infection rates of  
277 genotypes not targeted needs to be monitored.

### 278 **Future research directions**

279 The HPV genotypes with the highest infection rates provide opportunities for researchers  
280 to assess their health impact using human observational data. Carcinogenicity classification  
281 depends not only on animal data, but also on human trials or studies.[32] By following up  
282 individuals infected with HPV, it is possible to understand the impact of these HPV genotypes on  
283 health. The present study found that HPVs 54, 62, 74, and 86 are common and may be good  
284 candidates for long-term health studies.

285 Although these HPV genotypes are not directly targeted by vaccines, studies have shown  
286 that cross-reactivity with non-genital HPVs may be induced by vaccines.[44, 46] However, it is  
287 unclear whether cross-reactivity may be induced against the HPV genotypes with high infection  
288 rates. In the future, the impact of HPV vaccines on genotypes they target or do not target may be  
289 evaluated by using the data generated by large studies like the CHMS.

290 Over time, the use of HPV vaccines has been expanded to other age groups and males.[10]  
291 Thus, in the future, it is important to collect data not only on other HPV genotypes, but also on  
292 other population groups. The vaccinations against four or nine genotypes may cause spill-over  
293 effects or herd immunity on other genotypes[44] or population groups. The infection rates and  
294 vaccination history of other population groups may interact with the effectiveness of cervical  
295 cancer prevention. Long-term follow-up may be needed. With the expansion of vaccination  
296 programs, the cost effectiveness analysis of using HPV tests for primary cervical cancer  
297 screening[31] may need to be updated.

298 IARC HPV Prevalence Surveys conducted outside of Canada have reported a clustering  
299 of particular HPV genotypes.[47] With this knowledge in mind, we are planning to study  
300 whether HPV clustering patterns may differ in Canada.

301 A study has found that the HPV PCR tests reviewed by a HTA did not have perfect  
302 diagnostic test accuracy, i.e., 100% sensitivity and 100% specificity, for the detection of cervical  
303 cancerous lesions or cervical intraepithelial neoplasia (CIN).[2] Most of the PCR tests reviewed  
304 can detect 12 carcinogenic genotypes and 1 probably carcinogenic genotype, and report  
305 positivity if any one of these genotypes is detected.[31] Figure 1[8] shows that several possible  
306 carcinogenic genotypes and many genotypes associated with CIN[38] are not detected by  
307 currently available commercial PCR tests. It is unclear to what degree the lack of detection of  
308 possibly carcinogenic genotypes and those genotypes associated with CIN contributes to  
309 imperfect diagnostic test accuracy.

310 Last, herd immunity disturbs HPV infection in a population, and thus protects those who  
311 are unvaccinated. In the future, the benefits of HPV vaccination are likely to be seen in the  
312 reduction of the incidence of both genital and non-genital cancer.[45] The assessment of the  
313 magnitude of these benefits will depend on further data collection and analysis.

### 314 **Limitations**

315 The present study has the strength of a single data source, the CHMS, which reported  
316 vaccination status and which used consistent methods for HPV genotype quantification. Other  
317 studies may have depended on various sources to estimate infection rates, and so it is likely that  
318 many HPV genotypes were not tested and reported in the primary studies they reviewed.[36]  
319 However, the age ranges for vaccination status and HPV genotyping differed in the CHMS,



320 which leads to some difficulties in assessing the relationship between vaccination status and  
321 HPV infection by genotype.

322 Regarding a subgroup analysis, it is unlikely that Statistics Canada will grant its  
323 permission to release the infection rates or vaccination rates of subgroups that did not include  
324 large sample sizes. For example, it is unlikely that sufficient sample sizes exist for age-specific  
325 infection rates or city-wide infection rates. Moreover, the rates reported may not be applicable to  
326 subpopulations of specific characteristics. Only national rates are reported in this study.

327 The CHMS did not test for more than 46 HPV genotypes and several other genotypes  
328 associated with human diseases. For example, it did not test for HPVs 1, 2, and 4 that can cause  
329 common skin warts.[5, 38] It seems that the CHMS tested the HPV genotypes that were alpha  
330 types only.[5] Yet, it is unclear why these 46 genotypes were tested. We did not identify any  
331 CHMS documents that explain why these genotypes were selected for testing. Based on our  
332 results, we think strategies for choosing genotypes for surveillance can be refined.

## 333 Conclusion

334 Canada is one of the few countries that conducts national surveys to determine HPV  
335 infection rates by genotype, and it does not limit its surveillance to carcinogenic genotypes.[47]  
336 The HPV genotypes with highest infection rates among females aged 14 to 59 years are HPVs 16,  
337 62, 74, 54, 66, and 52 (3.42%, 2.14%, 2.1%, 2.04%, 1.83%, and 1.49%, respectively). With the  
338 age ranges expanded from 9 to 29 years to 9 to 59 years between 2009 to 2011 and 2012 to 2013,  
339 respectively, 890,197 and 1,427,000 females, respectively, were vaccinated against HPV in the  
340 two time periods of the two CHMS cycles. Discrepancies exist between the HPV genotypes  
341 whose infections are the most common, that can be detected by PCR tests, that are carcinogenic,  
342 and that can be prevented by vaccines.

343 For example, HPV 16 is carcinogenic, can be detected by PCR tests, can be prevented by  
344 vaccines, and is the most common infection among all genotypes. However, five of the seven  
345 genotypes (42, 54, 62, 66, and 74) with infection rates more than 1% cannot be detected by most  
346 commercially available PCR tests[2, 31] and are not targeted by vaccines. HPVs 6 and 11, whose  
347 infection rates were less than 1%, are associated with genital warts and can be prevented by  
348 vaccines, but cannot be detected by most commercially available PCR tests.[31] HPV 51 is  
349 carcinogenic, associated with genital warts, and can be detected by most commercially available  
350 PCR tests,[31] but is not targeted by vaccines. Researchers are developing PCR tests to detect  
351 more HPV genotypes[31] and are proposing methods to produce vaccines that can prevent HPV  
352 of other genotypes.[48] Currently, some genotypes with the highest infection rates in Canada are  
353 not targeted by PCR tests or vaccines. We recommend a better alignment of the genotypes  
354 targeted by HPV tests and vaccines with those genotypes with the highest infection rates in  
355 Canada.

## 356 Declaration

### 357 Required statement for the analysis of Statistics Canada data at the Research Data 358 Centre

359 The analysis presented in this paper was conducted at the Quebec Interuniversity Centre  
360 for Social Statistics (QICSS), which is part of the Canadian Research Data Centre Network  
361 (CRDCN). The services and activities provided by the QICSS are made possible by the financial  
362 or in-kind support of the Social Sciences and Humanities Research Council (SSHRC), the  
363 Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI),

364 Statistics Canada, the Fonds de recherche du Québec - Société et culture (FRQSC), the Fonds de  
365 recherche du Québec - Santé (FRQS) and the Quebec universities. The views expressed in this  
366 paper are those of the authors, and are not necessarily those of the CRDCN or its partners[25].

### 367 [Consent for publication](#)

368 The consent for publication was not required for this secondary data analysis.

### 369 [Acknowledgements](#)

370 Not applicable.

### 371 [Competing interests](#)

372 YSC is employed by the Canadian Agency for Drugs and Technologies in Health. YSC  
373 conducted this study as an independent researcher out of academic curiosity without any material  
374 support. No external funding was received for this study. This study is not associated with any  
375 patents, products in development or marketed products

### 376 [Authors' contribution](#)

377 YSC conceptualized and designed this study, managed and analyzed data, and drafted the  
378 manuscript.

### 379 [Availability of data and material](#)

380 It is against the Statistics Act of Canada to release the CHMS data. The collection of the  
381 CHMS data has been approved by the ethics committee within the governments of Canada. The  
382 CHMS data have been de-identified and maintained by Statistics Canada. The data can be  
383 accessed through the Research Data Centres administered by Statistics Canada. The details and  
384 eligibility for obtaining data access can be found online  
385 (<https://www.statcan.gc.ca/eng/rdc/process>).

### 386 [Funding](#)

387 No specific funding for this study.

388

## 389 References


- 390 1. Chao Y-S, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. HPV Testing for  
391 Primary Cervical Cancer Screening: A Health Technology Assessment. Canadian Agency for  
392 Drugs and Technologies in Health, Ottawa (ON); 2019.
- 393 2. Chao Y-S, Clark M, Ford C. HPV self-sampling for primary cervical cancer screening: a  
394 review of diagnostic test accuracy and clinical evidence. 2018.
- 395 3. Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, et al. European  
396 code against cancer 4th edition: infections and cancer. *Cancer epidemiology*. 2015;39:S120-S38.
- 397 4. Bird Y, Obidiya O, Mahmood R, Nwankwo C, Moraros J. Human papillomavirus  
398 vaccination uptake in Canada: a systematic review and meta-analysis. *International journal of*  
399 *preventive medicine*. 2017;8.
- 400 5. Crow JM. HPV: The global burden. *Nature*. 2012;488(7413):S2-S3.
- 401 6. Government of Canada. Human Papillomavirus (HPV) Ottawa, ON: Government of  
402 Canada; 2020 [updated Feb 14, 2020; cited 2020 Dec 12, 2020]. Available from:  
403 [https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-](https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/human-papillomavirus-hpv.html)  
404 [transmitted-infections/human-papillomavirus-hpv.html](https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/human-papillomavirus-hpv.html)
- 405 7. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human  
406 papillomavirus and related diseases report. L'Hospitalet de Llobregat: ICO Information Centre  
407 on HPV and Cancer. 2014.
- 408 8. ICO/IARC HPV Information Centre. Canada. Barcelona, Spain: ICO/IARC HPV  
409 Information Centre; 2019. Available from: [https://hpvcentre.net/statistics/reports/CAN\\_FS.pdf](https://hpvcentre.net/statistics/reports/CAN_FS.pdf).
- 410 9. Government of Canada. Human papillomavirus vaccine: Canadian Immunization Guide  
411 Ottawa, ON: Government of Canada; 2020 [updated Feb 12, 2020; cited 2020 Dec 12].  
412 Available from: [https://www.canada.ca/en/public-health/services/publications/healthy-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html)  
413 [living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html)  
414 [vaccine.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html).
- 415 10. Salvadori MI. Human papillomavirus vaccine for children and adolescents. *Paediatrics &*  
416 *child health*. 2018;23(4):262-5.
- 417 11. Canadian Cancer Society. Toronto HPV vaccine rate trails provincial average Toronto,  
418 ON: Canadian Cancer Society; 2016 [updated Sep 23, 2016; cited 2020 Dec 12]. Available from:  
419 [https://www.cancer.ca/en/about-us/for-media/media-releases/ontario/2016/sept/hpv-clinics-open-](https://www.cancer.ca/en/about-us/for-media/media-releases/ontario/2016/sept/hpv-clinics-open-for-boys/?region=on)  
420 [for-boys/?region=on](https://www.cancer.ca/en/about-us/for-media/media-releases/ontario/2016/sept/hpv-clinics-open-for-boys/?region=on).
- 421 12. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Drug trends among non-institutionalized  
422 Canadians and the impact of data collection changes in the Canadian Health Measures Survey  
423 2007 to 2015. *PloS one*. 2019;14(4):e0214718-e. doi: 10.1371/journal.pone.0214718. PubMed  
424 PMID: 30978234.
- 425 13. Chao YS, Wu HC, Wu CJ, Chen WC. Stages of Biological Development across Age: An  
426 Analysis of Canadian Health Measure Survey 2007-2011. *Front Public Health*. 2018;5(2296-  
427 2565 (Print)). doi: 10.3389/fpubh.2017.00355. eCollection 2017.
- 428 14. Chao Y-S, Wu H-C, Wu C-J, Chen W-C. Principal Component Approximation and  
429 Interpretation in Health Survey and Biobank Data. *Frontiers in Digital Humanities*. 2018;5(11).  
430 doi: 10.3389/fdigh.2018.00011.
- 431 15. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Trend analysis for national surveys:  
432 Application to all variables from the Canadian Health Measures Survey cycle 1 to 4. *PLOS ONE*.  
433 2018;13(8):e0200127. doi: 10.1371/journal.pone.0200127.

- 434 16. Giroux S. Canadian Health Measures Survey: sampling strategy overview. Health reports  
435 / Statistics Canada, Canadian Centre for Health Information = Rapports sur la sante / Statistique  
436 Canada, Centre canadien d'information sur la sante. 2007;18 Suppl:31-6.
- 437 17. Haines DA, Saravanabhavan G, Werry K, Houry C. An overview of human  
438 biomonitoring of environmental chemicals in the Canadian Health Measures Survey: 2007–2019.  
439 International Journal of Hygiene and Environmental Health. 2017;220(2, Part A):13-28. doi:  
440 <https://doi.org/10.1016/j.ijheh.2016.08.002>.
- 441 18. Tremblay MS, Connor Gorber S. Canadian health measures survey: brief overview. Can J  
442 Public Health. 2007;98(6):453-6. Epub 2008/12/02.
- 443 19. Carson V, Chaput J-P, Janssen I, Tremblay MS. Health associations with meeting new  
444 24-hour movement guidelines for Canadian children and youth. Preventive Medicine. 2017;95:7-  
445 13. doi: <http://dx.doi.org/10.1016/j.ypmed.2016.12.005>.
- 446 20. Statistics C. Population estimates on July 1st, by age and sex. Government of Canada.  
447 2016.
- 448 21. Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 2.  
449 Ottawa, ON: Statistics Canada, 2013 April. Report No.
- 450 22. Statistics Canada. Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 2  
451 Ottawa, ON: Statistics Canada; 2013 [updated April 12, 2013; cited 2020 Dec 12]. Available  
452 from: [https://www23.statcan.gc.ca/imdb-bmdi/document/5071\\_D2\\_T1\\_V2-eng.htm](https://www23.statcan.gc.ca/imdb-bmdi/document/5071_D2_T1_V2-eng.htm).
- 453 23. Chao Y-S, Wu C-J. PD26 Principal Component Approximation: Canadian Health  
454 Measures Survey. International Journal of Technology Assessment in Health Care.  
455 2019;34(S1):138-9. Epub 01/03. doi: 10.1017/S026646231800301X.
- 456 24. Statistics Canada. Canadian Health Measures Survey (CHMS) Content summary for  
457 cycles 1 to 8 In: Statistics Canada, editor. Ottawa, ON: Statistics Canada,; 2015.
- 458 25. The Quebec Inter-University Centre for Social Statistics (CIQSS). Statistics Canada Data  
459 Montreal, QC: The Quebec Inter-University Centre for Social Statistics (CIQSS),; 2017 [cited  
460 2017 Feb 1]. Available from: <https://www.ciqss.org/en/statistics-canada-data>.
- 461 26. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Composite  
462 diagnostic criteria are problematic for linking potentially distinct populations: the case of frailty.  
463 Scientific Reports. 2020;10(1):2601. doi: 10.1038/s41598-020-58782-1.
- 464 27. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Using syndrome  
465 mining with the Health and Retirement Study to identify the deadliest and least deadly frailty  
466 syndromes. Scientific reports. 2020;10(1):1-15.
- 467 28. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Opportunities and  
468 challenges from leading trends in a biomonitoring project: Canadian Health Measures Survey  
469 2007 to 2017. Frontiers in Public Health. 2020;8:460.
- 470 29. Chao Y-S, Lin K-F, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, et al. Simulation study to  
471 demonstrate biases created by diagnostic criteria of mental illnesses: major depressive episodes,  
472 dysthymia, and manic episodes. BMJ Open. 2020;10(11):e037022. doi: 10.1136/bmjopen-2020-  
473 037022.
- 474 30. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Opportunities and  
475 Challenges From Leading Trends in a Biomonitoring Project: Canadian Health Measures Survey  
476 2007–2017. Frontiers in Public Health. 2020;8:460.
- 477 31. Chao YS, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. HPV Testing for  
478 Primary Cervical Cancer Screening: A Health Technology Assessment. Ottawa, ON: Canadian

- 479 Agency for Drugs and Technologies in Health; 2019. Available from:  
480 <https://www.cadth.ca/sites/default/files/ou-tr/op0530-hpv-testing-for-pcc-report.pdf>.
- 481 32. World Health Organization, International Agency for Research on Cancer. Human  
482 papillomaviruses. Geneva, Switzerland: World Health Organization; 2007.
- 483 33. International Agency for Research on Cancer. Agents classified by the IARC  
484 monographs, volumes 1–128 Geneva, Switzerland: International Agency for Research on Cancer;  
485 2020 [cited 2020 Dec 24]. Available from: <https://monographs.iarc.fr/list-of-classifications>.
- 486 34. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human  
487 papillomavirus types: addressing the limits of epidemiology at the borderline. *Infectious agents*  
488 *and cancer*. 2009;4(1):8.
- 489 35. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology  
490 of human cancer. *Vaccine* 24 (Suppl 3): S1–S10. 2006.
- 491 36. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human  
492 papillomavirus and related diseases report in Canada. Barcelona, Spain: L'Hospitalet de  
493 Llobregat: ICO Information Centre on HPV and Cancer; 2019. Available from:  
494 <https://hpvcentre.net/statistics/reports/CAN.pdf>.
- 495 37. Rücker G, Carpenter JR, Schwarzer G. Detecting and adjusting for small-study effects in  
496 meta-analysis. *Biometrical Journal*. 2011;53(2):351-68. doi:  
497 <https://doi.org/10.1002/bimj.201000151>.
- 498 38. Burd EM. Human papillomavirus and cervical cancer. *Clinical microbiology reviews*.  
499 2003;16(1):1-17.
- 500 39. Meisal R, Rounge TB, Christiansen IK, Eieland AK, Worren MM, Molden TF, et al.  
501 HPV genotyping of modified general primer-amplicons is more analytically sensitive and  
502 specific by sequencing than by hybridization. *PloS one*. 2017;12(1):e0169074.
- 503 40. Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y. Estimates  
504 of the future burden of cancer attributable to infections in Canada. *Preventive Medicine*.  
505 2019;122:118-27. doi: <https://doi.org/10.1016/j.ypmed.2019.04.006>.
- 506 41. Shapiro GK, Perez S, Rosberger Z. Including males in Canadian human papillomavirus  
507 vaccination programs: a policy analysis. *Canadian Medical Association Journal*.  
508 2016;188(12):881. doi: 10.1503/cmaj.150451.
- 509 42. Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV  
510 vaccination introduction worldwide and WHO and UNICEF estimates of national HPV  
511 immunization coverage 2010–2019. *Preventive Medicine*. 2021;144:106399.
- 512 43. Goyette A, Yen GP, Racovitan V, Bhangu P, Kothari S, Franco EL. Evolution of Public  
513 Health Human Papillomavirus Immunization Programs in Canada. *Current Oncology*.  
514 2021;28(1):991-1007.
- 515 44. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity,  
516 Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-  
517 Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV  
518 Therapeutic Vaccines. *Clin Vaccine Immunol*. 2015;22(7):679-87. Epub 2015/05/06. doi:  
519 10.1128/CVI.00149-15. PubMed PMID: 25947147.
- 520 45. Chaturvedi AK, Graubard BI, Broutian T, Xiao W, Pickard RKL, Kahle L, et al.  
521 Prevalence of oral HPV infection in unvaccinated men and women in the United States, 2009-  
522 2016. *JAMA*. 2019;322(10):977-9.

- 523 46. Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, et al. Human Papillomavirus  
524 neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination  
525 with quadrivalent and bivalent HPV vaccines. *Vaccine*. 2016;34(13):1559-65.
- 526 47. Vaccarella S, Franceschi S, Snijders PJF, Herrero R, Meijer CJLM, Plummer M.  
527 Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC  
528 HPV Prevalence Surveys. *Cancer Epidemiology Biomarkers & Prevention*.  
529 2010;19(2):503. doi: 10.1158/1055-9965.EPI-09-0983.
- 530 48. Wang D, Liu X, Wei M, Qian C, Song S, Chen J, et al. Rational design of a multi-valent  
531 human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. *Nature*  
532 *communications*. 2020;11(1):1-15.
- 533  
534  
535  
536

537 Figure 1. HPV genotypes by infection rates, HPV tests, carcinogenicity, association with genital warts, and HPV vaccines.



538  
 539 \*In patients with epidermodysplasia verruciformis. HPV = human papillomavirus; IARC = International Agency for Research on  
 540 Cancer; PCR = Polymerase chain reaction. Infection rates are obtained from a national representative sample of females aged 14 to 59  
 541 years participating the Canadian Health Measures Survey. The HPV genotypes are listed in descending order of infection rates. The  
 542 HPV tests include the 13, 14, 15, and 19 HPV genotypes that are targeted by diagnostic tests using PCR.[1] The IARC classes are  
 543 obtained from the IARC database (<https://monographs.iarc.fr/list-of-classifications>).[8] The HPV genotypes associated with  
 544 Condyloma acuminata (genital warts) were obtained from a review.[38] The HPV vaccines include the 4 and 9 HPV genotypes that  
 545 these vaccines aim to prevent.[10] The same HPV genotypes are connected to each other across the categories.  
 546

